|
2025
|
P/S
|
Financial and insurance consultation services, namely, patient advisory, support and consultancy ... |
|
|
P/S
|
Education and training services, namely, seminars, providing non-downloadable webinars, and works... |
|
|
P/S
|
Providing healthcare information, medical information, and pharmaceutical information online, by ... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioede... |
|
2024
|
P/S
|
Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of... |
|
|
P/S
|
Medical services; medical information services; providing a website featuring medical and healthc... |
|
|
Invention
|
Modulators of apol1 expression.
The present embodiments provide methods, compounds, and composit... |
|
|
P/S
|
Medical services; medical information services; providing
medical and healthcare information for... |
|
|
Invention
|
Compositions and methods for modulating pkk expression.
Disclosed herein are antisense compounds... |
|
|
Invention
|
Compounds and methods for reducing atn1 expression. Provided are oligomeric agents, methods, and ... |
|
|
Invention
|
Compounds and methods for reducing tubb4a expression. Provided are compounds, methods, and pharma... |
|
|
Invention
|
Compositions and methods to treat liver, kidney and cell proliferative diseases and disorders. Di... |
|
|
Invention
|
Cd29 targeted oligonucleotides and uses thereof. The present disclosure provides compounds and me... |
|
|
Invention
|
Sugar modified oligonucleotides and uses thereof. The present disclosure provides RNAi agents com... |
|
|
P/S
|
Pharmaceuticals for treatment of genetic diseases and
disorders; pharmaceuticals for treatment o... |
|
|
Invention
|
Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression.
P... |
|
|
Invention
|
Compounds and methods for reducing pln expression.
Provided are oligomeric compounds, methods, a... |
|
|
Invention
|
Compounds and methods for reducing pln expression. Provided are oligomeric compounds, methods, an... |
|
|
Invention
|
Methods and compositions for inhibiting pmp22 expression.
The present embodiments provide method... |
|
|
Invention
|
Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof.
The present embodimen... |
|
|
Invention
|
Allele-selective compounds and methods for modulating huntingtin expression.
Provided herein are... |
|
|
Invention
|
Compounds and methods for reducing app expression.
Provided are compounds, methods, and pharmace... |
|
|
Invention
|
Compounds and methods for modulating alpha-synuclein expression. Provided herein are compounds, p... |
|
|
Invention
|
Allele-selective compounds and methods for modulating huntingtin expression. Provided herein are ... |
|
|
Invention
|
Compounds and methods for reducing app expression. Provided are compounds, methods, and pharmaceu... |
|
|
Invention
|
Devices and methods for storage of aqueous solutions of modified oligonucleotide compounds. |
|
|
Invention
|
Modulators of complement factor b.
The present embodiments provide methods, compounds, and compo... |
|
|
Invention
|
Compounds and methods for reducing atxn2 expression.
Provided are compounds, methods, and pharma... |
|
|
Invention
|
Compositions and methods for modulating apolipoprotein c-iii expression.
Provided herein are oli... |
|
2023
|
Invention
|
Selective antisense compounds and uses thereof.
The present invention provides oligomeric compou... |
|
|
P/S
|
Pharmaceutical preparations and substances for the treatment
of edema, namely hereditary angioed... |
|
|
Invention
|
Compounds and methods for reducing lrrk2 expression. Provided are compounds, methods, and pharmac... |
|
|
Invention
|
Compositions and methods for modulating apolipoprotein (a) expression.
Provided herein are oligo... |
|
|
Invention
|
Compounds and methods for increasing stmn2 expression.
Provided are compounds, methods, and phar... |
|
|
Invention
|
Compositions for modulating ataxin 2 expression.
Disclosed herein are antisense compounds and me... |
|
|
Invention
|
Modulators of enac expression.
The present embodiments provide methods, compounds, and compositi... |
|
|
Invention
|
Modulation of prekallikrein (pkk) expression.
Disclosed herein are antisense compounds and metho... |
|
|
P/S
|
Pharmaceutical research and development in the field of genetic diseases and disorders; providing... |
|
|
Invention
|
Selective reduction of allelic variants.
Disclosed herein are antisense compounds and methods fo... |
|
|
Invention
|
Compounds and methods for reducing dmpk expression.
Provided are oligomeric compounds, methods, ... |
|
|
Invention
|
Compounds and methods for reducing atxn3 expression.
Provided are compounds, methods, and pharma... |
|
|
Invention
|
Compounds and methods for modulating gfap.
Provided are compounds, methods, and pharmaceutical c... |
|
|
Invention
|
Selective antisense compounds and uses thereof.
The present disclosure provides oligomeric compo... |
|
|
Invention
|
Compounds and methods for modulating splicing of pre-mrna.
Provided are compounds, methods, and ... |
|
|
Invention
|
Conjugated antisense compounds and their use.
Provided herein are oligomeric compounds with conj... |
|
|
P/S
|
Pharmaceuticals; pharmaceuticals in the fields of autosomal dominant, autosomal recessive, geneti... |
|
|
Invention
|
Conjugated antisense compounds and their use.
The present disclosure provides half duplex compou... |
|
|
Invention
|
Compounds and methods for modulating plp1.
Provided are compounds, methods, and pharmaceutical c... |
|
|
P/S
|
Pharmaceutical research and development in the field of autosomal dominant, autosomal recessive, ... |
|
|
Invention
|
Modulating apolipoprotein (a) expression.
Provided herein are oligomeric compounds with conjugat... |
|
|
P/S
|
Diagnostic preparations and human therapeutics for medical
use, namely, antisense oligonucleotid... |
|
2022
|
Invention
|
Compounds and methods for modulating glycogen synthase 1.
Provided are compounds, methods, and p... |
|
|
P/S
|
Diagnostic preparations and human therapeutics for medical use, namely, antisense oligonucleotide... |
|
|
Invention
|
Conjugated oligonucleotides and uses thereof.
Provided herein are oligomeric compounds comprisin... |
|
|
Invention
|
Compounds and methods for modulating scn1a expression.
Provided are oligomeric compounds, method... |
|
|
Invention
|
Linkage modified oligomeric compounds and uses thereof.
The present disclosure provides oligomer... |
|
|
Invention
|
Modulation of nox4 expression.
Provided herein are methods, antisense agents, specific inhibitor... |
|
|
Invention
|
Method for synthesis of linkage modified oligomeric compounds.
The present disclosure provides m... |
|
|
Invention
|
Compounds for modulating unc13a expression.
Provided are oligomeric compounds and pharmaceutical... |
|
|
Invention
|
Compounds for reducing ptbp1 expression.
Provided are oligomeric agents, oligomeric compounds, a... |
|
|
Invention
|
Modulation of coasy expression.
Provided herein are specific inhibitors, compositions, methods a... |
|
|
Invention
|
Compounds and methods for modulating huntingtin.
Provided are compounds, methods, and pharmaceut... |
|
|
Invention
|
Compounds and methods for reducing dux4 expression.
Provided are compounds, pharmaceutical compo... |
|
2021
|
Invention
|
Compounds and methods for reducing kcnt1 expression.
Provided are compounds, methods, and pharma... |
